Nanobodies which are single-domain antibodies derived from the Variable Heavy domain of Heavy-chain-only antibodies (VHHs) found in camels and sharks, represent a novel approach for enhancing the detection and neutralization of food toxins. Botulinum neurotoxin (BoNT), a potent neurotoxin produced by Clostridium botulinum, can cause severe poisoning even in minimal amounts (approximately 1 - 2 ng/kg), necessitating the development of highly sensitive detection methods. In this study, we recombinantly synthesized the nanobodies ALc-B8 (A8) and JNE-B10 (J10), which specifically bind to the light chains of BoNT type A (BoNT/A) and BoNT type B (BoNT/B), respectively. Optimal conditions for expressing nanobodies A8 (33 kDa) and J10 (32 kDa) were identified using the pET28a vector in Escherichia coli BL21 (DE3) RIL bacteria, with induction by 0.5 mM IPTG at an OD600 of approximately 0.6 - 0.8 for 16 - 18 hours at 16℃. The purified nanobodies A8 and J10, yielding 10 - 20 mg/L of culture, were able to specifically recognize the recombinant BoNT/A and BoNT/B light chains at a concentration of 100 μg/mL in Western blotting. These findings provide a foundation for the application of these nanobodies in the detection and neutralization of botulinum toxins.
Nanobody, VHH, botulinum, food toxin, neutralization, recombinant protein
[1]. J. P. Salvador, L. Vilaplana, and M. P. Marco, "Nanobody: outstanding features for diagnostic and therapeutic applications," Analytical and Bioanalytical Chemistry, vol. 411, no. 9, pp. 1703-1713, 2019, doi: 10.1007/s00216-019-01633-4.
[2]. S. S. Arnon, R. Schecter, T. V. Inglesby, et al., "Botulinum toxin as a biological weapon: Medical and public health management," Journal of the American Medical Association, vol. 285, no. 8, 2001, pp. 1059-1070, doi: 10.1001/jama.285.8.1059.
[3]. G. Yao, K. H. Lam, J. Weisemann, et al., "A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding," Scientific Reports, vol. 7, no. 1, pp. 7438, 2017, doi: 10.1038/s41598-017-07457-5.
[4]. D. Kumaran, R. Rawat, S. A. Ahmed, and S. Swaminathan, "Substrate binding mode and its implication on drug design for botulinum neurotoxin A," PLOS Pathogens, vol. 4, no. 9, 2008, doi: 10.1371/journal.ppat.1000165.
[5]. J. M. Tremblay, C. L. Kuo, C. Abeijon, et al., "Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases," Journal of the International Society on Toxinology, vol. 56, no. 6, pp. 990-998, 2010, doi: 10.1016/j.toxicon.2010.07.003.
[6]. S. I. Miyashita, J. Zhang, S. Zhang, C. B. Shoemaker, and M. Dong, "Delivery of single-domain antibodies into neurons using a chimeric toxin–based platform is therapeutic in mouse models of botulism," Science Translational Medicine, vol. 13, no. 575, 2021, doi: 10.1126/SCITRANSLMED.AAZ4197.
[7]. P. M. Mcnutt, E. J. Vazquez-Cintron, L. Tenezaca, et al., "Neuronal delivery of antibodies has therapeutic effects in animal models of botulism," Science Translational Medicine, vol. 13, no. 575, 2021, doi:10.1126/scitranslmed.abd7789.
[8]. K. ho Lam, J. M. Tremblay, E. Vazquez-Cintron, et al., "Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum Neurotoxins," Cell Reports, vol. 30, no. 8, pp. 2526-2539, 2020, doi: 10.1016/j.celrep.2020.01.107.
[9]. K. H. Lam, J. M. Tremblay, K. Perry, K. Ichtchenko, C. B. Shoemaker, and R. Jin, "Probing the structure and function of the protease domain of botulinum neurotoxins using single-domain antibodies," PLOS Pathogens, vol. 18, no. 1, 2022, doi: 10.1371/journal.ppat.1010169.
[10]. U. K. Laemmli, "Cleavage of structural proteins during the assembly of the head of bacteriophage T4," Nature, vol. 227, no. 5259, pp. 680-685, 1970, doi: 10.1038/227680a0.
[11]. G. C. Girt, A. Lakshminarayanan, J. Huo, et al., "The use of nanobodies in a sensitive ELISA test for SARS-CoV-2 Spike 1 protein," Royal Society Open Science, vol. 8, no. 9, pp. 211016, 2021, doi: 10.1098/rsos.211016.